<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02513810</url>
  </required_header>
  <id_info>
    <org_study_id>1-2015-0040</org_study_id>
    <nct_id>NCT02513810</nct_id>
  </id_info>
  <brief_title>A Randomized Controlled Comparison Between One Versus More Than Six Months of Dual Antiplatelet Therapy After Biolimus A9-eluting Stent Implantation</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      DES are preferred over BMS for most patients, however prolonged dual antiplatelet therapy is&#xD;
      required for patients treated with DES for prevention of late or very late stent thrombosis.&#xD;
      which increases a risk of major bleeding. BioFreedom is a Biolimus A9-coated stent that&#xD;
      consists of a stainless steel stent platform with a textured abluminal surface without use of&#xD;
      any polymer in the coating. Biolimus A9 rapid release and polymer-free property may give&#xD;
      BioFreedom the advantages of both DES and BMS that may require less duration of DAPT.&#xD;
      BioMatrix Flex, Biolimus-eluting stent with biodegradable polymer, also demonstrated safety&#xD;
      and efficacy. We will compare these two difference types of Biolimus A9-eluting stents with&#xD;
      different duration of DAPT. With proven adequate and safe duration, we will compare between&#xD;
      one versus more than six months of dual antiplatelet therapy after Biolimus A9-eluting stents&#xD;
      implantation using different properties of BioFreedom and BioMatrix Flex.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2, 2015</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Actual">September 17, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of major adverse cardiovascular events</measure>
    <time_frame>1 year</time_frame>
    <description>events including cardiac death, nonfatal myocardial infarction, target vessel revascularization, major bleeding and cerebrovascular accident</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3020</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Short-term DAPT after Biofreedom</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Long-term DAPT after BioMatrix or Ultimaster</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BioFreedom with 1 month DAPT</intervention_name>
    <description>The cath lab will follow site standard operating procedures for PTCA and stenting. Information will be collected and recorded on the treated study vessel including angiographic parameters. Dual antiplatelet therapy after PCI will be continued for 1 month.</description>
    <arm_group_label>Short-term DAPT after Biofreedom</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BioMatrix or Ultimaster with 6 to 12 months DAPT</intervention_name>
    <description>The cath lab will follow site standard operating procedures for PTCA and stenting. Information will be collected and recorded on the treated study vessel including angiographic parameters. Dual antiplatelet therapy after PCI will be the duration of dual antiplatelet therapy will be 6 to 12 months at the discretion of the interventionist.</description>
    <arm_group_label>Long-term DAPT after BioMatrix or Ultimaster</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients â‰¥ 19 years old&#xD;
&#xD;
          -  Patients with ischemic heart disease who are considered for coronary revascularization&#xD;
             with PCI&#xD;
&#xD;
          -  Significant coronary de novo lesion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute myocardial infarction&#xD;
&#xD;
          -  Complex lesion morphologies such as aorta-ostial, unprotected left main, chronic total&#xD;
             occlusion, graft, thrombosis, heavy calcified (definite calcified lesions on&#xD;
             angiogram) or extremely tortuous lesion&#xD;
&#xD;
          -  Need to use of dual antiplatelet therapy more than 1 month because of other medical&#xD;
             conditions&#xD;
&#xD;
          -  Cardiogenic shock or experience of cardiopulmonary resuscitation&#xD;
&#xD;
          -  Contraindication or hypersensitivity to Biolimus A9, stainless steel, heparin,&#xD;
             antiplatelet agents or contrast media&#xD;
&#xD;
          -  History of documented prior cerebrovascular attack within 6 months&#xD;
&#xD;
          -  Treated with any stent within 3 months&#xD;
&#xD;
          -  Reference vessel diameter &lt;2.25 mm or &gt;4.0 mm&#xD;
&#xD;
          -  Pregnant women or women with potential childbearing&#xD;
&#xD;
          -  Inability to follow the patient over the period of 1 year after enrollment, as&#xD;
             assessed by the investigator&#xD;
&#xD;
          -  Inability to understand or read the informed content&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 31, 2015</study_first_submitted>
  <study_first_submitted_qc>July 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2015</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

